Saudi Arabia’s quiet LDT move is bigger than it looks
The MDS-G022 lays the foundation for a GCC-wide in-house IVD framework. This matters for diagnostics sovereignty and early commercial development in the Gulf In May 2025, the Saudi Food and Drug Authority published Version 2.0 of MDS-G022, its guidance on in-house IVDs. Most commentary has treated it as a compliance update for lab managers. I want…